Anna Kondic
Bristol-Myers Squibb (United States)(US)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Statistical Methods in Clinical Trials, CAR-T cell therapy research, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Evaluation of dosing strategy for pembrolizumab for oncology indications(2017)247 cited
- → Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance(2018)207 cited
- → Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer(2016)159 cited
- → Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors(2016)147 cited
- → Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response(2017)135 cited
- → A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model(2014)76 cited
- → Immunogenicity of pembrolizumab in patients with advanced tumors(2019)54 cited
- → MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis(2014)53 cited
- → Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma(2016)25 cited
- → Navigating Between Right, Wrong, and Relevant: The Use of Mathematical Modeling in Preclinical Decision Making(2022)12 cited